The IGF-1 receptor as a therapeutic target to improve endothelial progenitor cell function

Molecular Medicine

Volumn 14, Issue 5-6, 2008, Pages 235-237

  Fleissner, Felix ^a   Thum, Thomas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; N(G),N(G) DIMETHYLARGININE; SOMATOMEDIN C RECEPTOR;

ANGIOGENESIS; CARDIOVASCULAR RISK; CELL FUNCTION; DIABETES MELLITUS; DRUG BINDING; ENDOTHELIUM CELL; ENZYME RELEASE; HEART INFARCTION; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STEM CELL;

EID: 44649098785     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2008-00037.Fleissner     Document Type: Note

References (16)

1. Bauersachs J, Thum T. (2007) Endothelial progenitor cell dysfunction: mechanisms and therapeutic approaches. Eur. J. Clin. Invest. 37:603-6.
2. Aicher A et al. (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9:1370-6.
3. Heissig B et al. (2003) Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 109:625-637.
4. Werner N et al. (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353:999-1007.
5. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. (2005) Platelet receptor inhibition in ischemic syndrome management (PRISM) investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 110:3206-12.
6. Thum T et al. (2007) Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes. 56:666-74.
7. Thum T et al. (2007) Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ. Res. 100:434-43.
8. Thum T et al. (2007) Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J. Clin. Endocrinol. Metab. 92:4172-9.
9. Humpert PM et al. (2008) Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor dependent signaling. Mol. Med. 14:301-308.
10. Böger RH et al. (1996) Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J. Clin. Invest. 98:2706-13.
11. Franklin VL, Khan F, Kennedy G, Belch JJ, Greene SA. (2008) Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia. 51:353-6.
12. Nathan Cleary PA et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353:2643-53.
13. Kurtzhals P et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 49:999-1005.
14. Thum T et al. (2005) Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J. Am. Coll. Cardiol. 46:1693-701.
15. Ellger B et al. (2008) Glycemic control modulates arginine- and ADMA-levels during critical illness by preserving DDAH-activity. Endocrinology. 2008, Feb 21 [Epub ahead of print].
16. Bogdanski P et al. (2007) Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int. J. Clin. Pharmacol. Ther. 45:563-7.